Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to do an analysis on UPS stock, UNP stock and ISRG stock.

3 extracted signals · 3 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
23 Aug 2025, 19:05 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to do an analysis on UPS stock, UNP stock and ISRG stock.
Source overview

AI-generated source summary

The video provides a fundamental analysis of UPS, Union Pacific (UNP), and Intuitive Surgical (ISRG). UPS is down 45% over the last five years and while the CEO bought $1 million worth of stock at around $85.67 and a director bought $432.48k shares around the same price the company is structurally declining, with market share halved since 2014, so a target of $80 is given. The discussion of UNP indicates that it is close to its 52 week low trading at $224 and that 26% of Ferromex (Mexican railroad) is owned by UNP, he aims for the company to trade at $180 a share. For ISRG, the video mentions Chinese competition impacting earnings and while has recurring revenue. The stock is targeting a $372 price range.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
3
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
3
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
3 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  4. Market predictions extracted

    3 eligible signals linked to this case.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.6
Tracked signals
324
Historical success
34.4%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail